# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pfizer announced it will advance development of its once-daily Danuglipron.
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Pha...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...
Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to $30.
This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European indus...
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases The re...